Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

INTRODUCTION: There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Peter, Farouk, Mourad, Manamley, Nick, Addison, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898130/
https://www.ncbi.nlm.nih.gov/pubmed/24173670
http://dx.doi.org/10.1007/s12325-013-0063-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898130/
https://www.ncbi.nlm.nih.gov/pubmed/24173670
http://dx.doi.org/10.1007/s12325-013-0063-y

Ejemplares similares